Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Doug who wrote (881)	1/9/2002 10:39:22 PM
From: Doug	Respond to of 3044

IMCL record now opened to the public is ample proof of the state of many BIO-Tech firms. In additon to Proteomics& Genetics, they have also acquired a taste for data manipulation.!

To: Doug who wrote (881)	1/10/2002 1:42:31 AM
From: Miljenko Zuanic	Read Replies (3) \| Respond to of 3044

<<M.Z: The probability of success in development of a new Breakthru drug has been very low. I believed that using Proteomics and Genomics this would increase. IMCL has clearly show that this is not the case.>> IMCL has nothing to do with G/P. They license C225, and target was well known for some time. <<Infact the risk of skewed data being presented has increased as it is now easier to manipulate data.>> Today, it is harder to manipulate data. Everything is available electronically. <<As such the risk associated with investment in the new age Start ups is no different than the olde ones. Hence they may not deserve the high valuations that thay have.>> What startup? What valuations? <<To increase valuation, they must increase success rates or drastically reduce time for each project.>> To develop new drugs they need to do right things. Time isn't that important, but cost to develop it is. <<Cos like LU, CHIR , MLNM, CRA, HGSI all have excellent world class Labs & good Scientists but lack the focus , zeal and drive to improve shareholders worth. They are driven by an addiction to science which results in a lot of patents , papers and pure research most of which lacks any practical applications in the immediate future. In brief they are not focussed on applied research with set goals ,deliverables and accountability all of which are essential in the making of a great CO. Compare the strides made by the Networking world and that made by the BIo-Tech world.>> You know ZERO what it takes to develop drug. BS leave to somebody else, not me. <<A check of the No of patents/stock price is a good indicator of which Cos have no applied focus.>> In 99% cases patents are distraction to competitors. <<Nevertheless the Scientist gain a big MAC ( Mutual admiration Club) membership , attending seminars around the world, plagiarizing from each other and defending the club against any accountabilty.>> I am not Scientist, so can not speak for them. <<I am not "short" but a realist.!>> You have no idea what is MLNM business plan and how will be materialized, and when, and at what success rate? Recent MLNM business move indicate that they are very serious. Ask Aventis or Abbott, if you do not believe me. I am not short or long. I did trade MLNM two times last year, and will do again this year. Based on street mood and opinion. Miljenko